Corrigendum to “Investigation of the enhanced antitumor potency of CD46-specific chimeric antigen receptor-T cells in human colorectal cancer liver metastases after combination with nanotherapeutics”[Nano Today, 52 (2023), 101985] (Nano Today (2023) 52, (S1748013223002347), (10.1016/j.nantod.2023.101985))

The authors regret an unintentional misuse of the image of the NC-CAR T+rAd-R/I (Day 14) group inFig. 4E. The images showed the same in the first and third mice. The authors regret an unintentional misuse of the image of the CD46-CAR T (Day 14) group in Fig. 4E. The images showed the same in the second and third mice. The authors regret an unintentional misuse of the image of the third mouse of the CD46-CAR T (Day 21) group in Fig. 4E. The images showed the same as the first mouse of the CD46-CAR T+rAd-R/I (Day 21) group. The authors believe that these errors can be misleading and therefore should be corrected. This correction does not influence any of the experimental results and discussion or the conclusions reported in the paper. The authors would like to apologise for any inconvenience caused.